1. Home
  2. F vs REGN Comparison

F vs REGN Comparison

Compare F & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ford Motor Company

F

Ford Motor Company

N/A

Current Price

$12.18

Market Cap

56.2B

ML Signal

N/A

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

N/A

Current Price

$781.32

Market Cap

79.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
F
REGN
Founded
1903
1988
Country
United States
United States
Employees
169000
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.2B
79.4B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
F
REGN
Price
$12.18
$781.32
Analyst Decision
Hold
Buy
Analyst Count
15
24
Target Price
$13.09
$819.54
AVG Volume (30 Days)
67.4M
617.3K
Earning Date
01-01-0001
04-16-2026
Dividend Yield
4.94%
0.49%
EPS Growth
N/A
8.19
EPS
N/A
41.48
Revenue
N/A
$5,872,227,000.00
Revenue This Year
N/A
$11.69
Revenue Next Year
$0.95
$10.06
P/E Ratio
N/A
$18.31
Revenue Growth
N/A
20.82
52 Week Low
$8.44
$476.49
52 Week High
$14.80
$821.11

Technical Indicators

Market Signals
Indicator
F
REGN
Relative Strength Index (RSI) 30.72 52.19
Support Level $11.19 $740.39
Resistance Level $14.18 $786.67
Average True Range (ATR) 0.43 21.05
MACD -0.23 -2.04
Stochastic Oscillator 10.29 68.99

Price Performance

Historical Comparison
F
REGN

About F Ford Motor Company

Ford Motor Co. manufactures automobiles under its Ford and Lincoln brands. In March 2022, the company announced that it will run its combustion engine business, Ford Blue, and its BEV business, Ford Model e, as separate businesses but still all under Ford Motor. The company has over 13% market share in the United States, about 10% share in the UK, and just over 1% share in China including Taiwan and unconsolidated affiliates. Sales in the US made up about 65% of 2025 total company revenue. Ford has about 169,000 employees, including about 56,300 UAW employees, and is based in Dearborn, Michigan.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: